Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. (2022)

First Author: Captur G
Attributed to:  Phase 1 COVID-19 Immunity - National Core Study funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.104293

PubMed Identifier: 36182629

Publication URI: http://europepmc.org/abstract/MED/36182629

Type: Journal Article/Review

Volume: 85

Parent Publication: EBioMedicine

ISSN: 2352-3964